NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.27 -0.13 (-2.41 %) (As of 11/13/2018 03:19 PM ET)Previous Close$5.40Today's Range$5.25 - $5.5552-Week Range$4.36 - $15.20Volume5,661 shsAverage Volume411,081 shsMarket Capitalization$134.61 millionP/E Ratio-1.83Dividend YieldN/ABeta2.63 ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts. Receive SNDX News and Ratings via Email Sign-up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNDX Previous Symbol CUSIPN/A Webwww.syndax.com Phone781-419-1400 Debt Debt-to-Equity RatioN/A Current Ratio5.63 Quick Ratio5.63 Price-To-Earnings Trailing P/E Ratio-1.83 Forward P/E Ratio-1.79 P/E GrowthN/A Sales & Book Value Annual Sales$2.11 million Price / Sales62.04 Cash FlowN/A Price / CashN/A Book Value$4.28 per share Price / Book1.23 Profitability EPS (Most Recent Fiscal Year)($2.90) Net Income$-60,800,000.00 Net Margins-3,185.75% Return on Equity-91.11% Return on Assets-64.69% Miscellaneous Employees44 Outstanding Shares24,840,000Market Cap$134.61 million OptionableOptionable Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions What is Syndax Pharmaceuticals' stock symbol? Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX." How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals Inc (NASDAQ:SNDX) released its earnings results on Monday, November, 5th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.08. The company earned $0.38 million during the quarter, compared to analysts' expectations of $0.38 million. Syndax Pharmaceuticals had a negative net margin of 3,185.75% and a negative return on equity of 91.11%. View Syndax Pharmaceuticals' Earnings History. When is Syndax Pharmaceuticals' next earnings date? Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 4th 2019. View Earnings Estimates for Syndax Pharmaceuticals. What price target have analysts set for SNDX? 4 equities research analysts have issued 12-month price objectives for Syndax Pharmaceuticals' shares. Their predictions range from $6.00 to $40.00. On average, they expect Syndax Pharmaceuticals' stock price to reach $20.25 in the next year. This suggests a possible upside of 284.3% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals. What is the consensus analysts' recommendation for Syndax Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals. What are Wall Street analysts saying about Syndax Pharmaceuticals stock? Here are some recent quotes from research analysts about Syndax Pharmaceuticals stock: 1. According to Zacks Investment Research, "Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. " (11/10/2018) 2. HC Wainwright analysts commented, "Valuation: We base our $30 price target on probability-adjusted revenue forecasts for entinostat in combination with other drugs in advanced HR+, HER2- breast cancer, NSCLC, and metastatic melanoma. We use the net present value of our revenue forecast through 2027, apply a 35% POS for HR+, HER2- breast cancer, and 10% POS for NSCLC and melanoma, with a 3x price/sales multiple, and we value the early stage pipeline at $10 million, the amount of the upfront payments the company made to acquire the menin inhibitors and SNDX-6352, to arrive at our price target." (7/12/2018) Has Syndax Pharmaceuticals been receiving favorable news coverage? Press coverage about SNDX stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Syndax Pharmaceuticals earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. Who are some of Syndax Pharmaceuticals' key competitors? Some companies that are related to Syndax Pharmaceuticals include Basilea Pharmaceutica (BPMUF), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), ChemoCentryx (CCXI), Prothena (PRTA), Xeris Pharmaceuticals (XERS), Aurinia Pharmaceuticals (AUPH), Dova Pharmaceuticals (DOVA), Rigel Pharmaceuticals (RIGL), Kezar Life Sciences (KZR), Eidos Therapeutics (EIDX), Odonate Therapeutics (ODT), TG Therapeutics (TGTX), Theratechnologies (THERF) and Progenics Pharmaceuticals (PGNX). Who are Syndax Pharmaceuticals' key executives? Syndax Pharmaceuticals' management team includes the folowing people: Dr. Briggs W. Morrison, CEO & Director (Age 58)Mr. Michael A. Metzger, Pres & COO (Age 47)Mr. Richard P. Shea, CFO & Treasurer (Age 66)Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 67)Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 49) When did Syndax Pharmaceuticals IPO? (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Syndax Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.08%), Dimensional Fund Advisors LP (3.20%), FMR LLC (1.40%), Panagora Asset Management Inc. (0.63%), Bridgeway Capital Management Inc. (0.41%) and Bank of New York Mellon Corp (0.20%). View Institutional Ownership Trends for Syndax Pharmaceuticals. Which major investors are selling Syndax Pharmaceuticals stock? SNDX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Syndax Pharmaceuticals. Which major investors are buying Syndax Pharmaceuticals stock? SNDX stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, BlackRock Inc., Panagora Asset Management Inc., Bridgeway Capital Management Inc. and Claraphi Advisory Network LLC. View Insider Buying and Selling for Syndax Pharmaceuticals. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Syndax Pharmaceuticals' stock price today? One share of SNDX stock can currently be purchased for approximately $5.27. How big of a company is Syndax Pharmaceuticals? Syndax Pharmaceuticals has a market capitalization of $134.61 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe. What is Syndax Pharmaceuticals' official website? The official website for Syndax Pharmaceuticals is http://www.syndax.com. How can I contact Syndax Pharmaceuticals? Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected] MarketBeat Community Rating for Syndax Pharmaceuticals (NASDAQ SNDX)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 193 (Vote Outperform)Underperform Votes: 201 (Vote Underperform)Total Votes: 394MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/13/2018 by MarketBeat.com StaffFeatured Article: What is a balanced fund?